Declining business revenue and widening operating, ordinary and net losses
First written in FY2017-Q3. 15 of 40 entries say "Worsened", first in FY2017. Latest entry: FY2027-H1.
SanBio moved to the "Worse" side of this theme in 2025, 5 years after the typical company in this theme (2020).
The whole theme swung hardest in 2020: 28 of 87 companies on the "Worse" side.
51 other companies' latest entry also says "Other".
- FY2027-H1Operating loss increased; ordinary and net losses decreasedAnnual report
「Against this backdrop, during the six months ended 30 September, costs related mainly to obtaining partial approval for a change in the manufacturing and marketing approval conditions for Acugo® resulted in the recognition of ¥1,226 million in research and development expenses, and the operating loss was ¥1,909 million, compared with an operating loss of ¥1,888 million in the previous interim period. Meanwhile, a foreign exchange gain of ¥185 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥1,730 million, compared with an ordinary loss of ¥2,481 million in the previous interim period, and an interim net loss attributable to owners of the parent of ¥1,791 million, compared with an interim net loss attributable to owners of the parent of ¥1,997 million.」
Business revenue remained zero. The operating loss widened slightly due to costs related to obtaining partial approval for a change in Acugo®'s approval conditions, while the ordinary loss and interim net loss narrowed from the previous interim period due to foreign exchange gains. - 2026-06-15MitigatedEarnings
「The operating loss was ¥953 million, compared with an operating loss of ¥1,007 million in the same quarter of the previous consolidated fiscal year.」
Although business revenue remained zero, the operating loss for the quarter narrowed from the same quarter of the previous fiscal year. - FY2026WorsenedAnnual report
「Against this backdrop, during the fiscal year, costs related mainly to obtaining partial approval for a change in the manufacturing and marketing approval conditions for Acugo® resulted in the recognition of ¥2,678 million in research and development expenses, and the operating loss was ¥3,794 million, compared with an operating loss of ¥3,516 million in the previous fiscal year. Meanwhile, a foreign exchange loss of ¥326 million arising from exchange-rate fluctuations was recorded as a non-operating expense, resulting in an ordinary loss of ¥4,291 million, compared with an ordinary loss of ¥3,022 million in the previous fiscal year, and a net loss attributable to owners of the parent of ¥3,842 million, compared with a net loss attributable to owners of the parent of ¥2,882 million.」
Business revenue remained zero, while the operating loss, ordinary loss and net loss for the year widened from the previous year due to the recognition of research and development expenses and a foreign exchange loss. - FY2026-H1WorsenedAnnual report
「Against this backdrop, during the six months ended 30 September, costs related mainly to obtaining partial approval for a change in the manufacturing and marketing approval conditions for Acugo® resulted in the recognition of ¥1,346 million in research and development expenses, and the operating loss was ¥1,888 million, compared with an operating loss of ¥1,571 million in the previous interim period. Meanwhile, a foreign exchange loss of ¥518 million arising from exchange-rate fluctuations was recorded as a non-operating expense, resulting in an ordinary loss of ¥2,481 million, compared with an ordinary loss of ¥1,186 million in the previous interim period, and an interim net loss attributable to owners of the parent of ¥1,997 million, compared with an interim net loss attributable to owners of the parent of ¥1,309 million.」
Business revenue remained zero, while the operating loss, ordinary loss and interim net loss attributable to owners of the parent all widened from the previous interim period. - FY2025Operating loss narrowed; ordinary and net losses widenedAnnual report
「Research and development expenses of ¥2,357 million were recorded, resulting in an operating loss of ¥3,516 million, compared with an operating loss of ¥4,539 million in the previous fiscal year. Meanwhile, a foreign exchange gain of ¥622 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥3,022 million, compared with an ordinary loss of ¥2,824 million in the previous fiscal year, and a net loss attributable to owners of the parent of ¥2,882 million, compared with a net loss attributable to owners of the parent of ¥2,644 million in the previous fiscal year.」
The operating loss narrowed due to lower research and development expenses and other costs, while the ordinary loss widened due to lower foreign exchange gains, and the net loss attributable to owners of the parent also widened. - FY2025-H1MitigatedAnnual report
「Against this backdrop, during the six months ended 30 September, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥1,024 million in research and development expenses, and the operating loss was ¥1,571 million, compared with an operating loss of ¥3,084 million in the previous interim period. Meanwhile, a foreign exchange gain of ¥397 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥1,186 million, compared with an ordinary loss of ¥1,930 million in the previous interim period, and an interim net loss attributable to owners of the parent of ¥1,309 million, compared with an interim net loss attributable to owners of the parent of ¥1,787 million.」
Business revenue remained zero, but the operating loss, ordinary loss and interim net loss attributable to owners of the parent all narrowed from the same period of the previous year due to lower research and development expenses and foreign exchange gains. - FY2025-Q1MitigatedAnnual report
「Against this backdrop, during the three months ended 30 June, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥387 million in research and development expenses, and the operating loss was ¥666 million, compared with an operating loss of ¥1,461 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥767 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in ordinary income of ¥91 million, compared with an ordinary loss of ¥937 million in the same period of the previous year. The quarterly net loss attributable to owners of the parent was ¥144 million, compared with a quarterly net loss attributable to owners of the parent of ¥626 million.」
Business revenue remained zero, but the operating loss narrowed due to lower research and development expenses, ordinary income turned positive due to foreign exchange gains, and the quarterly net loss attributable to owners of the parent also narrowed. - FY2024MitigatedAnnual report
「Against this backdrop, during the fiscal year, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥2,849 million in research and development expenses, and the operating loss was ¥4,539 million, compared with an operating loss of ¥7,899 million in the previous fiscal year. Meanwhile, a foreign exchange gain of ¥1,746 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥2,824 million, compared with an ordinary loss of ¥4,698 million in the previous fiscal year, and a net loss attributable to owners of the parent of ¥2,644 million, compared with a net loss attributable to owners of the parent of ¥5,559 million in the previous fiscal year.」
Business revenue remained zero, but the operating loss, ordinary loss and net loss attributable to owners of the parent all narrowed from the previous year due to lower research and development expenses and foreign exchange gains. - FY2024-Q3Zero business revenue; operating loss narrowed, ordinary loss returned, net loss widenedAnnual report
「Against this backdrop, during the nine months ended 31 December, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥2,447 million in research and development expenses, and the operating loss was ¥3,725 million, compared with an operating loss of ¥6,404 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥1,912 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥1,837 million, compared with ordinary income of ¥437 million in the same period of the previous year. The quarterly net loss attributable to owners of the parent was ¥1,883 million, compared with a quarterly net loss attributable to owners of the parent of ¥1,758 million.」
Business revenue remained zero. The operating loss narrowed due to lower research and development expenses, including manufacturing-related costs, while ordinary income turned into an ordinary loss due to lower foreign exchange gains, and the net loss widened. - FY2024-Q2Zero business revenue; operating and net losses narrowed, ordinary loss widenedAnnual report
「Against this backdrop, during the six months ended 30 September, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥2,112 million in research and development expenses, and the operating loss was ¥3,084 million, compared with an operating loss of ¥4,621 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥1,172 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥1,930 million, compared with an ordinary loss of ¥774 million in the same period of the previous year. The quarterly net loss attributable to owners of the parent was ¥1,787 million, compared with a quarterly net loss attributable to owners of the parent of ¥2,154 million.」
Business revenue remained zero. The operating loss narrowed from the same period of the previous year due to manufacturing-related costs and other expenses associated with obtaining approval, and the quarterly net loss attributable to owners of the parent also narrowed, while the ordinary loss widened from ¥774 million to ¥1,930 million due to lower foreign exchange gains. - FY2024-Q1Zero business revenue; operating loss narrowed, ordinary loss returned, net loss widenedAnnual report
「Against this backdrop, during the three months ended 30 June, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥1,048 million in research and development expenses, and the operating loss was ¥1,461 million, compared with an operating loss of ¥1,844 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥534 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥937 million, compared with ordinary income of ¥869 million in the same period of the previous year. The quarterly net loss attributable to owners of the parent was ¥626 million, compared with a quarterly net loss attributable to owners of the parent of ¥315 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss narrowed due to lower research and development expenses, while foreign exchange gains decreased from ¥2,729 million to ¥534 million, causing ordinary income to turn into an ordinary loss and the net loss to widen. - FY2023Zero business revenue; operating and net losses widened, ordinary loss widened slightlyAnnual report
「During the fiscal year, research and development expenses of ¥6,118 million and an operating loss of ¥7,899 million were recorded due to higher costs resulting from the weaker yen, increased manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval, and higher costs resulting from the reclassification of commercial production materials previously recorded as supplies for research and development use. In addition, a foreign exchange gain of ¥3,326 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥4,698 million, compared with an ordinary loss of ¥4,579 million in the previous fiscal year, and a net loss attributable to owners of the parent of ¥5,559 million, compared with a net loss attributable to owners of the parent of ¥4,677 million in the previous fiscal year.」
Business revenue remained zero. Research and development expenses and the operating loss increased due to manufacturing-related costs and other expenses associated with obtaining approval. Although foreign exchange gains partially offset the loss, the ordinary loss and net loss for the year also widened from the previous year. - FY2023-Q3Zero business revenue; operating loss widened, ordinary income turned positive, net loss narrowedAnnual report
「Against this backdrop, during the nine months ended 31 December, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥4,981 million in research and development expenses, and the operating loss was ¥6,404 million, compared with an operating loss of ¥4,739 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥6,885 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in ordinary income of ¥437 million, compared with an ordinary loss of ¥3,032 million in the same period of the previous year. After recording ¥2,194 million in deferred income taxes, the quarterly net loss attributable to owners of the parent was ¥1,758 million, compared with a quarterly net loss attributable to owners of the parent of ¥3,115 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss widened due to manufacturing-related costs and other expenses associated with obtaining approval, while ordinary income turned positive at ¥437 million due to foreign exchange gains, and the net loss narrowed after the recognition of deferred income taxes. - FY2023-Q2Zero business revenue; operating loss widened, ordinary loss narrowed, net loss increased slightlyAnnual report
「Against this backdrop, during the six months ended 30 September, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for approval resulted in the recognition of ¥3,620 million in research and development expenses, and the operating loss was ¥4,621 million, compared with an operating loss of ¥3,052 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥3,879 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥774 million, compared with an ordinary loss of ¥2,146 million in the same period of the previous year. After recording ¥1,379 million in deferred income taxes, the quarterly net loss attributable to owners of the parent was ¥2,154 million, compared with a quarterly net loss attributable to owners of the parent of ¥2,134 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss widened from ¥3,052 million to ¥4,621 million due to manufacturing-related costs and other expenses associated with obtaining approval, while the ordinary loss narrowed from ¥2,146 million to ¥774 million due to foreign exchange gains. The quarterly net loss attributable to owners of the parent increased slightly from ¥2,134 million to ¥2,154 million due to the recognition of deferred income taxes. - FY2023-Q1Zero business revenue; operating loss widened, ordinary income turned positive, net loss narrowedAnnual report
「Against this backdrop, during the three months ended 30 June, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥1,370 million in research and development expenses, and the operating loss was ¥1,844 million, compared with an operating loss of ¥1,540 million in the same period of the previous year. Meanwhile, a foreign exchange gain of ¥2,729 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in ordinary income of ¥869 million, compared with an ordinary loss of ¥855 million in the same period of the previous year. After recording ¥1,184 million in deferred income taxes, the quarterly net loss attributable to owners of the parent was ¥315 million, compared with a quarterly net loss attributable to owners of the parent of ¥860 million.」
Business revenue remained zero, while the operating loss widened due to higher research and development expenses. Foreign exchange gains resulted in ordinary income of ¥869 million, and the net loss narrowed to ¥315 million after the recognition of deferred income taxes. - FY2022Zero business revenue; operating loss widened, ordinary loss narrowed, net loss widenedAnnual report
「Against this backdrop, during the fiscal year, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥4,955 million in research and development expenses. The operating loss was ¥6,620 million, compared with an operating loss of ¥5,801 million in the previous fiscal year. In addition, a foreign exchange gain of ¥1,961 million arising from exchange-rate fluctuations was recorded as non-operating income, resulting in an ordinary loss of ¥4,579 million, compared with an ordinary loss of ¥6,530 million in the previous fiscal year. The net loss attributable to owners of the parent was ¥4,677 million, compared with a net loss attributable to owners of the parent of ¥3,385 million in the previous fiscal year.」
Business revenue remained zero. The operating loss widened due to costs related to the application for approval, but the ordinary loss narrowed due to foreign exchange gains, while the net loss attributable to owners of the parent widened due to a decrease in extraordinary gains and other factors. - FY2022-Q3Zero business revenue; operating loss widened, ordinary and net losses narrowedAnnual report
「Against this backdrop, during the nine months ended 31 December, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥3,546 million in research and development expenses. The operating loss was ¥4,739 million, compared with an operating loss of ¥4,188 million in the same period of the previous year, the ordinary loss was ¥3,032 million, compared with an ordinary loss of ¥4,839 million, and the quarterly net loss attributable to owners of the parent was ¥3,115 million, compared with a quarterly net loss attributable to owners of the parent of ¥4,841 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss widened due to higher research and development expenses, including manufacturing-related costs associated with the application for approval, while the ordinary loss and quarterly net loss attributable to owners of the parent narrowed due to foreign exchange gains, gains on debt forgiveness and other factors. - FY2022-Q2Zero business revenue; operating loss widened, ordinary and net losses narrowedAnnual report
「Against this backdrop, during the six months ended 30 September, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥2,251 million in research and development expenses. The operating loss was ¥3,052 million, compared with an operating loss of ¥2,570 million in the same period of the previous year, the ordinary loss was ¥2,146 million, compared with an ordinary loss of ¥3,205 million, and the quarterly net loss attributable to owners of the parent was ¥2,134 million, compared with a quarterly net loss attributable to owners of the parent of ¥3,207 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss widened due to higher research and development expenses, while the ordinary loss and quarterly net loss attributable to owners of the parent narrowed due to foreign exchange gains and other factors. - FY2022-Q1Zero business revenue; operating loss widened, ordinary and net losses narrowedAnnual report
「During the three months ended 30 June, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥1,126 million in research and development expenses. The operating loss was ¥1,540 million, compared with an operating loss of ¥1,242 million in the same period of the previous year, the ordinary loss was ¥855 million, compared with an ordinary loss of ¥1,505 million, and the quarterly net loss attributable to owners of the parent was ¥860 million, compared with a quarterly net loss attributable to owners of the parent of ¥1,507 million.」
Business revenue remained zero, as in the same period of the previous year. The operating loss widened from ¥1,242 million to ¥1,540 million, mainly due to higher research and development expenses, while the ordinary loss narrowed from ¥1,505 million to ¥855 million and the quarterly net loss attributable to owners of the parent narrowed from ¥1,507 million to ¥860 million due to the recognition of foreign exchange gains. - FY2021Zero business revenue; operating and ordinary losses widened, net loss narrowedAnnual report
「During the fiscal year, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥4,071 million in research and development expenses. The operating loss was ¥5,801 million, compared with an operating loss of ¥5,486 million in the previous fiscal year. In addition, a foreign exchange loss of ¥634 million arising from exchange-rate fluctuations was recorded as a non-operating expense, resulting in an ordinary loss of ¥6,530 million, compared with an ordinary loss of ¥5,146 million in the previous fiscal year. Furthermore, a gain on the sale of investment securities of ¥3,318 million was recorded as an extraordinary gain following the sale of investment securities held by the Company, resulting in a net loss attributable to owners of the parent of ¥3,385 million, compared with a net loss attributable to owners of the parent of ¥5,157 million in the previous fiscal year.」
Business revenue remained zero after the termination of the agreement with Sumitomo Dainippon Pharma, and the operating and ordinary losses widened. Meanwhile, the net loss attributable to owners of the parent narrowed due to gains on the sale of investment securities, including shares in CareNet. - FY2021-Q3WorsenedAnnual report
「During the nine months ended 31 December, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥2,974 million in research and development expenses. The operating loss was ¥4,188 million, compared with an operating loss of ¥3,628 million in the same period of the previous year, the ordinary loss was ¥4,839 million, compared with an ordinary loss of ¥3,271 million, and the quarterly net loss attributable to owners of the parent was ¥4,841 million, compared with a quarterly net loss attributable to owners of the parent of ¥3,280 million.」
With no business revenue recorded, the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent widened from the same period of the previous year. - FY2021-Q2WorsenedAnnual report
「Against this backdrop, during the six months ended 30 September, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥1,798 million in research and development expenses. The operating loss was ¥2,570 million, compared with an operating loss of ¥2,385 million in the same period of the previous year, the ordinary loss was ¥3,205 million, compared with an ordinary loss of ¥2,039 million, and the quarterly net loss attributable to owners of the parent was ¥3,207 million, compared with a quarterly net loss attributable to owners of the parent of ¥2,048 million.」
No business revenue was recorded during the quarter, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent widened from the same period of the previous year. - FY2021-Q1WorsenedAnnual report
「During the three months ended 30 June, manufacturing-related costs associated mainly with the SB623 chronic-stage traumatic brain injury program in preparation for its application for approval resulted in the recognition of ¥857 million in research and development expenses. The operating loss was ¥1,242 million, compared with an operating loss of ¥1,248 million in the same period of the previous year, the ordinary loss was ¥1,505 million, compared with an ordinary loss of ¥727 million, and the quarterly net loss attributable to owners of the parent was ¥1,507 million, compared with a quarterly net loss attributable to owners of the parent of ¥736 million.」
The operating loss narrowed slightly year on year, while business revenue fell from ¥189 million in the same period of the previous year to zero, and the ordinary loss and quarterly net loss attributable to owners of the parent widened. - FY2020WorsenedAnnual report
「Business revenue for the fiscal year amounted to ¥447 million, compared with ¥741 million in the previous year. The operating loss was ¥5,486 million, compared with an operating loss of ¥3,733 million in the previous year, following the recognition of ¥4,327 million in research and development expenses.」
Business revenue decreased from ¥741 million to ¥447 million, while the operating loss widened from ¥3,733 million to ¥5,486 million, the ordinary loss was ¥5,146 million, and the net loss attributable to owners of the parent widened to ¥5,157 million. - FY2020-Q3WorsenedAnnual report
「Business revenue for the nine months ended 31 December amounted to ¥424 million, compared with ¥568 million in the same period of the previous year. The operating loss was ¥3,628 million, compared with an operating loss of ¥2,479 million in the same period of the previous year, following the recognition of ¥2,862 million in research and development expenses, including clinical trial expenses related to the two development programs for chronic-stage cerebral infarction and chronic-stage traumatic brain injury described above. In addition, ¥489 million in non-operating income was recognized as grants from the California Institute for Regenerative Medicine (CIRM), resulting in an ordinary loss of ¥3,271 million, compared with an ordinary loss of ¥1,547 million in the same period of the previous year, and a quarterly net loss attributable to owners of the parent of ¥3,280 million, compared with a quarterly net loss attributable to owners of the parent of ¥1,549 million.」
Business revenue decreased year on year, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all widened. - FY2020-Q2Business revenue increased; operating, ordinary and net losses widenedAnnual report
「Against this backdrop, business revenue for the six months ended 30 September amounted to ¥427 million, compared with ¥415 million in the same period of the previous year, mainly reflecting development milestone payments and other revenue received under the SB623 joint development and sales licensing agreement entered into by the Group with Sumitomo Dainippon Pharma Co., Ltd. in North America. The operating loss was ¥2,385 million, compared with an operating loss of ¥1,615 million in the same period of the previous year, following the recognition of ¥2,013 million in research and development expenses, including clinical trial expenses related to the two development programs for chronic-stage cerebral infarction and chronic-stage traumatic brain injury described above. In addition, ¥493 million in non-operating income was recognized as grants from the California Institute for Regenerative Medicine (CIRM), resulting in an ordinary loss of ¥2,039 million, compared with an ordinary loss of ¥1,040 million in the same period of the previous year, and a quarterly net loss attributable to owners of the parent of ¥2,048 million, compared with a quarterly net loss attributable to owners of the parent of ¥1,041 million.」
Business revenue increased from ¥415 million to ¥427 million year on year, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all widened. - FY2020-Q1Increase in business revenue and operating loss; decrease in ordinary lossAnnual report
「Business revenue for the cumulative first quarter of the current fiscal year was ¥189 million (¥158 million in the same period of the previous year). Operating loss was ¥1,248 million (¥1,004 million), following the recognition of ¥1,095 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. In addition, the Company recorded ¥290 million in non-operating income representing grants from CIRM and ¥237 million in foreign exchange gains, resulting in an ordinary loss of ¥727 million (¥836 million) and a quarterly net loss attributable to owners of the parent of ¥736 million (¥837 million).」
Business revenue increased year on year, while the operating loss widened. The ordinary loss and the quarterly net loss attributable to owners of the parent narrowed, due to CIRM grants and foreign exchange gains. - FY2019MitigatedAnnual report
「Business revenue for the current consolidated fiscal year was ¥741 million (¥490 million in the same period of the previous year). Operating loss was ¥3,733 million (¥4,378 million), following the recognition of ¥3,721 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. In addition, due to the recognition of ¥927 million in non-operating income representing grants from CIRM, ordinary loss was ¥2,919 million (¥3,947 million), and net loss attributable to owners of the parent was ¥2,920 million (¥3,940 million).」
Business revenue increased from ¥490 million to ¥742 million, while the operating loss, ordinary loss and net loss attributable to owners of the parent all decreased from the previous year. - FY2019-Q3MitigatedAnnual report
「Against this backdrop, revenue from development support payments and other income received under the SB623 co-development and sales licensing agreement concluded by the Group with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥568 million for the cumulative third quarter of the current fiscal year (¥371 million in the same period of the previous year). Operating loss was ¥2,479 million (¥3,169 million), following the recognition of ¥2,497 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. In addition, the Company recorded ¥675 million in non-operating income representing grants from CIRM and ¥325 million in foreign exchange gains, resulting in an ordinary loss of ¥1,547 million (¥3,164 million) and a quarterly net loss attributable to owners of the parent of ¥1,549 million (¥3,158 million).」
Compared with the same period of the previous year, business revenue increased, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased. - FY2019-Q2MitigatedAnnual report
「Against this backdrop, revenue from development support payments and other income received under the SB623 co-development and sales licensing agreement concluded by the Group with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥415 million for the cumulative second quarter of the current fiscal year (¥249 million in the same period of the previous year). Operating loss was ¥1,615 million (¥2,149 million), following the recognition of ¥1,669 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. In addition, the Company recorded ¥472 million in non-operating income representing grants from CIRM and ¥165 million in foreign exchange gains, resulting in an ordinary loss of ¥1,040 million (¥2,282 million) and a quarterly net loss attributable to owners of the parent of ¥1,041 million (¥2,276 million).」
Compared with the same period of the previous year, business revenue increased from ¥249 million to ¥415 million, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased. - FY2019-Q1MitigatedAnnual report
「Against this backdrop, revenue from development support payments and other income received under the SB623 co-development and sales licensing agreement concluded by the Group with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥158 million for the cumulative first quarter of the current fiscal year (¥123 million in the same period of the previous year). Operating loss was ¥1,004 million (¥1,021 million), following the recognition of ¥972 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. In addition, the Company recorded ¥135 million in non-operating income representing grants from the California Institute for Regenerative Medicine (CIRM) and ¥47 million in foreign exchange gains, resulting in an ordinary loss of ¥836 million (¥1,098 million) and a quarterly net loss attributable to owners of the parent of ¥837 million (¥1,097 million).」
Compared with the same period of the previous year, business revenue increased from ¥123 million to ¥158 million, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased. - FY2018WorsenedAnnual report
「Business revenue was ¥490 million (¥949 million in the same period of the previous year). Operating loss was ¥4,378 million (¥1,932 million), following the recognition of ¥4,156 million in research and development expenses, including clinical trial costs related to the two development programs for chronic ischemic stroke and chronic traumatic brain injury described above. Net loss attributable to owners of the parent was ¥3,940 million (¥1,835 million).」
Business revenue decreased from ¥949 million to ¥490 million, while the operating loss and net loss attributable to owners of the parent increased. - FY2018-Q3WorsenedAnnual report
「Against this backdrop, revenue from development support payments and other income received under the SB623 co-development and sales licensing agreement concluded by the Group with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥371 million for the cumulative third quarter of the current fiscal year (¥758 million in the same period of the previous year) and an operating loss of ¥3,169 million (¥1,214 million). In addition, mainly due to the recognition of ¥69 million in foreign exchange gains, ordinary loss was ¥3,164 million (¥1,813 million), and quarterly net loss attributable to owners of the parent was ¥3,158 million (¥1,691 million).」
Compared with the same period of the previous year, business revenue decreased from ¥758 million to ¥371 million, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all increased. - FY2018-Q2WorsenedAnnual report
「Against this backdrop, revenue from development support payments and other income received under the SB623 co-development and licensing agreement concluded by the Group with Dainippon Sumitomo Pharma Co., Ltd. in North America resulted in business revenue of ¥249 million for the cumulative second quarter of the current fiscal year (¥684 million in the same period of the previous year) and an operating loss of ¥2,149 million (¥610 million). In addition, mainly due to the recognition of ¥121 million in foreign exchange losses, ordinary loss was ¥2,282 million (¥1,228 million), and quarterly net loss attributable to owners of the parent was ¥2,276 million (¥1,145 million).」
Compared with the same period of the previous year, business revenue decreased from ¥684 million to ¥249 million, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all increased. - FY2018-Q1WorsenedAnnual report
「Against this backdrop, the Company received development support payments under its SB623 co-development and licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. in North America for the U.S. Phase 2b clinical trial for chronic ischemic stroke. As a result, business revenue for the cumulative first quarter of the current fiscal year was ¥123 million (¥625 million in the same period of the previous year). Operating loss was ¥1,021 million (operating income of ¥77 million), following the recognition of ¥929 million in research and development expenses, including clinical trial costs related to the two development programs described above. In addition, mainly due to the recognition of ¥65 million in foreign exchange losses, ordinary loss was ¥1,098 million (¥320 million), and quarterly net loss attributable to owners of the parent was ¥1,097 million (¥277 million).」
Compared with the same period of the previous year, business revenue decreased from ¥625 million to ¥123 million, operating results shifted from income of ¥77 million to a loss of ¥1,021 million, and the ordinary loss and quarterly net loss attributable to owners of the parent also increased. - FY2017WorsenedAnnual report
「Business revenue for the current consolidated fiscal year was ¥949 million (¥1,174 million in the previous consolidated fiscal year). Operating loss was ¥1,932 million (¥1,125 million), following the recognition of ¥2,058 million in research and development expenses, including clinical trial costs related to the two development programs described above. In addition, mainly due to the recognition of ¥199 million in foreign exchange losses, ordinary loss was ¥2,166 million (¥1,172 million), and net loss attributable to owners of the parent was ¥1,835 million (¥988 million).」
Compared with the previous fiscal year, business revenue decreased, and the operating loss, ordinary loss and net loss attributable to owners of the parent all increased. - FY2017-Q3First statedAnnual report
「Against this backdrop, under the SB623 co-development and licensing agreement concluded with Dainippon Sumitomo Pharma Co., Ltd. in North America, the Company received milestone revenue of US$5 million upon enrollment of the first subject in the U.S. Phase 2b clinical trial for chronic ischemic stroke, as well as development support payments and other revenue. As a result, business revenue for the cumulative third quarter of the current fiscal year was ¥758 million (¥1,099 million in the same period of the previous year), operating loss was ¥1,214 million (¥566 million), ordinary loss was ¥1,813 million (¥608 million), due to the recording of ¥8 million in interest expense and ¥565 million in foreign exchange losses, and the quarterly net loss attributable to owners of the parent was ¥1,691 million (¥470 million).」
Compared with the same period of the previous year, business revenue decreased, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all increased.